Aurobindo gets final USFDA nod for pre-surgery sedation drug
news2016-03-17
3 Views
2
"The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Dexmedetomidine Hydrochloride Injection, 200 mcg (base)/2 mL (100 mcg (base)/mL) single-dose vials," Aurobindo Pharma said in a BSE filing today.
Latest News from Moneycontrol.com
The news, reports, views and opinions of authors (or source) expressed are their own and do not necessarily represent the views of CRWE World.
